Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-18T08:54:36.231Z Has data issue: false hasContentIssue false
  • English
  • Français

Decreased monocyte chemoattractant protein 1 and relationship with 15-deoxy Δ12,14-prostaglandin J2 in gamma-linolenic acid supplemented healthy subjects

Published online by Cambridge University Press:  04 June 2010

M. Xiang ,
E. Pinto ,
M. A. Rahman ,
M. Leach  and
L. S. Harbige
M. Xiang
Affiliation:
Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK
E. Pinto
Affiliation:
Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK
M. A. Rahman
Affiliation:
Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK
M. Leach
Affiliation:
Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK
L. S. Harbige
Affiliation:
Centre for Biosciences Research, School of Science, University of Greenwich, Kent ME4 4TB, UK
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Type
Abstract
Information
Proceedings of the Nutrition Society , Volume 69 , Issue OCE3: 3rd Immunonutrition Workshop, 21–24 October 2009, Girona, Spain , 2010 , E325
Copyright
Copyright © The Authors 2009

In this pilot study, we investigated the effects on monocyte chemoattractant protein 1 (MCP-1; CCL2) secretion, MCP-1 gene expression and 15-deoxy Δ12,14-prostaglandin J2 (15d-PGJ2) production in peripheral blood mononuclear cells (PBMCs) of gamma-linolenic acid (GLA, 18:3 n−6) rich-borage oil supplemented healthy volunteers. GLA is rapidly converted to dihomo-gamma-linolenic acid (DGLA, 20:3 n−6) and in some cells desaturated further to arachidonic acid (AA, 20:4 n−6). In this study, we present data as seven healthy volunteers acting as their own controls who ingested 14 g borage oil per day consecutively for 13 weeks. It was found that the MCP-1 production from phytohaemagglutinin (PHA)-stimulated PBMCs was significantly reduced during the time course of the supplementation (Table). In addition, the level of PBMC MCP-1 gene expression was reduced significantly during the supplementation period (Table). A significant positive correlation was found between the expression of MCP-1 gene and MCP-1 production in stimulated cell cultures. There was a significant increase in stimulated 15d-PGJ2 production at weeks 7 and 13 (Table) and a significant negative correlation between 15d-PGJ2 production and MCP-1 production (Figure). In a parallel study using 14 g of corn oil [which contains linoleic acid (LA, 18:2 n−6) but no GLA] preliminary findings suggest no changes in MCP-1 (week 0, 1462±163 pg/ml v. week 13, 1045±73 pg/ml). The study suggests therefore that GLA-rich borage oil supplementation in humans results in the inhibition of PBMC MCP-1 expression at the gene and protein levels and that 15d-PGJ2, a metabolite of AA known to inhibit MCP-1, appears to be the mechanism by which GLA-rich borage oil inhibits MCP-1. The effects of GLA-rich borage oil on PBMC MCP-1 expression and production may be beneficial in certain chronic inflammatory diseases where MCP-1 has been strongly implicated.

Comparison between groups supplemented borage oil for weeks 4, 7 and 13, respectively and week 0 (without borage oil supplementation). *P<0.05, **P<0.01 and ***P<0.001.